Expert panel backs Moderna shots after full US approval
A federal advisory panel has voted to continue to endorse Moderna’s COVID-19 vaccine for U.S. adults
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A federal advisory panel voted unanimously Friday to continue to endorse Moderna s COVID-19 vaccine for adults, now that U.S. regulators have given the shots their full approval.
The decision has little practical effect. Tens of millions of Americans have already gotten Moderna shots, following its emergency authorization by the Food and Drug Administration more than a year ago.
Earlier this week, the FDA gave the product full licensure, following the kind of rigorous, time-consuming review given to other vaccines.
While the FDA licenses vaccines, the Centers for Disease Control and Prevention makes recommendations to doctors and patients about how they should be used. So the CDC's Advisory Committee on Immunization Practices took up the matter on Friday.
The panel heard summaries of medical studies that showed the vaccine is working against the coronavirus and there is no evidence of new safety concerns.
The Moderna vaccine, now being marketed under the name Spikevax, is licensed as a two-dose series for people 18 and older. Under earlier emergency use authorizations, additional doses can be given as additional doses for people with weakened immune systems or as half-dose boosters.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.